Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common shares, Euro 0.12 nominal value per share
-
Shares outstanding
-
26,019,256
-
Total 13F shares
-
10,325,473
-
Share change
-
+2,320,542
-
Total reported value
-
$16,107,942
-
Put/Call ratio
-
40%
-
Price per share
-
$1.56
-
Number of holders
-
21
-
Value change
-
+$3,784,170
-
Number of buys
-
10
-
Number of sells
-
6
Institutional Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) as of Q3 2025
As of 30 Sep 2025,
LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) was held by
21 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
10,325,473 shares.
The largest 10 holders included
Shay Capital LLC, Redmile Group, LLC, BML Capital Management, LLC, Sanofi, Merck & Co., Inc., GTS SECURITIES LLC, Rangeley Capital, LLC, PNC Financial Services Group, Inc., CITADEL ADVISORS LLC, and ROYAL BANK OF CANADA.
This page lists
21
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.